Format

Send to

Choose Destination
Sci Rep. 2017 Apr 6;7:46176. doi: 10.1038/srep46176.

Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.

Author information

1
School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
2
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
3
School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.

Abstract

To address the shortcomings of cystoscopy and urine cytology for detecting and grading bladder cancer (BC), ultrahigh performance liquid chromatography (UHPLC) coupled with Q-TOF mass spectrometry in conjunction with univariate and multivariate statistical analyses was employed as an alternative method for the diagnosis of BC. A series of differential serum metabolites were further identified for low-grade(LG) and high-grade(HG) BC patients, suggesting metabolic dysfunction in malignant proliferation, immune escape, differentiation, apoptosis and invasion of cancer cells in BC patients. In total, three serum metabolites including inosine, acetyl-N-formyl-5-methoxykynurenamine and PS(O-18:0/0:0) were selected by binary logistic regression analysis, and receiver operating characteristic (ROC) test based on their combined use for HG BC showed that the area under the curve (AUC) was 0.961 in the discovery set and 0.950 in the validation set when compared to LG BC. Likewise, this composite biomarker panel can also differentiate LG BC from healthy controls with the AUC of 0.993 and 0.991 in the discovery and validation set, respectively. This finding suggested that this composite serum metabolite signature was a promising and less invasive classifier for probing and grading BC, which deserved to be further investigated in larger samples.

PMID:
28382976
PMCID:
PMC5382774
DOI:
10.1038/srep46176
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center